+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Devic's Syndrome Treatment Market - Global Forecast 2025-2030- Product Image
Devic's Syndrome Treatment Market - Global Forecast 2025-2030- Product Image
Sale

Devic's Syndrome Treatment Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977777
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Devic's Syndrome Treatment Market is experiencing dynamic evolution as advanced immunotherapies and digital health solutions reshape care models and stakeholder priorities. This concise analysis equips senior leaders with the actionable intelligence required to navigate emerging clinical, operational, and regulatory shifts in this rare autoimmune segment.

Market Snapshot: Devic's Syndrome Treatment Market

The global Devic’s Syndrome Treatment Market grew from USD 220.27 million in 2024 to USD 230.71 million in 2025. With an expected CAGR of 4.70%, the market is projected to reach USD 290.17 million by 2030. This measured expansion is driven by breakthroughs in targeted therapies, growing adoption of digital monitoring, and evolving policy support for rare disease management, shaping a competitive yet opportunity-rich landscape.

Scope & Segmentation

  • Treatment Types: Includes corticosteroids (intravenous, oral), immunosuppressants (azathioprine, mycophenolate mofetil), monoclonal antibodies (eculizumab, inebilizumab), plasma exchange (automated, manual), and supportive therapy (pain management, physiotherapy).
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies all play pivotal roles in delivering therapies across acute, outpatient, and home-care settings.
  • End Users: Home healthcare providers, hospitals managing acute episodes, and specialty clinics overseeing ongoing patient care all drive product utilization and adoption patterns.
  • Geographic Coverage: Regional analysis spans the Americas, Europe, Middle East, Africa, and Asia Pacific, featuring deep dives for key markets in the United States, Canada, Latin America, EU, MENA, and Asia-Pacific economies like Japan, China, and Australia.
  • Key Companies Covered: Analysis includes Alexion Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Viela Bio, Inc., Chugai Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.

Key Takeaways for Decision-Makers

  • Emerging immunotherapies and next-generation targeted agents are transforming long-term management strategies, pushing providers to continually re-evaluate clinical algorithms and patient pathways.
  • The integration of digital health tools into monitoring and adherence workflows is elevating real-world data capture, enabling more personalized and proactive care interventions.
  • Strategic collaborations among pharmaceutical manufacturers, academic institutions, and specialty care networks are accelerating product development and market introduction, tightening the feedback loop from bench to bedside.
  • Distribution strategies—spanning from hospital-based models to online pharmacy platforms—directly influence access, lead times, and the overall patient experience, creating differentiators among providers.
  • Regulatory landscapes are adapting, with accelerated pathways and multi-stakeholder partnerships expediting approvals for rare disease therapies, but adoption barriers remain, particularly in under-resourced regions.

Tariff Impact and Supply Chain Considerations

Recent U.S. tariff implementations have increased manufacturing costs for monoclonal antibody-based therapies by raising the price of imported biologic components. In response, pharmaceutical companies are evaluating supply network structures, localizing production where feasible, and renegotiating procurement strategies to buffer downstream delivery impacts. Hospitals and payers are adapting through closer purchasing alignment, while value-based contracts and risk-sharing agreements are being explored to allocate increased financial burdens more equitably across stakeholders.

Methodology & Data Sources

This report is built on a multi-stage research process, combining thorough literature reviews with structured interviews of subject matter experts. Data triangulation was implemented to cross-validate market insights, while targeted consultations with clinicians, pharmacoeconomists, and supply chain managers ensured multidimensional accuracy and operational relevance.

Why This Report Matters for Senior Decision-Makers

  • Enables resource planning and market entry strategies through granular segmentation analysis and actionable geographic insights.
  • Supports investment prioritization by illuminating emerging technology trends, clinical best practices, and external disruptors impacting patient access and operational continuity.
  • Provides a validated foundation for internal discussions on pipeline prioritization, care delivery optimization, and stakeholder engagement in a rapidly evolving therapeutic area.

Conclusion

This analysis sets a clear agenda for navigating the evolving Devic's Syndrome Treatment Market. Executives leveraging these insights will be better positioned to inform strategy, optimize operations, and drive enduring value across the treatment continuum.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of neuromyelitis optica therapies with improved specificity and safety profiles
5.2. Integration of real-world evidence and patient registries in clinical decision support for Devic's syndrome
5.3. Increasing investment in monoclonal antibody pipeline focusing on aquaporin-4 targeted treatments for Devic's syndrome
5.4. Emergence of biosimilars and novel biologics driving cost competition in Devic's syndrome management
5.5. Growing significance of telemedicine and remote monitoring devices for neuromyelitis optica patient care
5.6. Expansion of genetic and biomarker research enabling personalized treatment strategies for Devic's syndrome
5.7. Collaborative partnerships between pharma and biotech accelerating Devic's syndrome therapy innovation
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Devic's Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Corticosteroids
8.2.1. Intravenous
8.2.2. Oral
8.3. Immunosuppressants
8.3.1. Azathioprine
8.3.2. Mycophenolate Mofetil
8.4. Monoclonal Antibodies
8.4.1. Eculizumab
8.4.2. Inebilizumab
8.5. Plasma Exchange
8.5.1. Automated
8.5.2. Manual
8.6. Supportive Therapy
8.6.1. Pain Management
8.6.2. Physiotherapy
9. Devic's Syndrome Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Devic's Syndrome Treatment Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Devic's Syndrome Treatment Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Devic's Syndrome Treatment Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Devic's Syndrome Treatment Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Alexion Pharmaceuticals, Inc.
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.3. Viela Bio, Inc.
14.3.4. Chugai Pharmaceutical Co., Ltd.
14.3.5. Teva Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET: RESEARCHAI
FIGURE 22. DEVIC'S SYNDROME TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 23. DEVIC'S SYNDROME TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 24. DEVIC'S SYNDROME TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 106. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 107. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 108. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 109. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 110. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 111. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 112. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 113. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 114. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 115. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 126. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 127. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 208. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 209. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 212. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 213. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 224. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 225. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 228. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 229. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 252. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 253. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 254. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 255. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 256. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 257. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 258. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 259. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 260. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 261. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 272. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 273. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 276. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 277. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA DEVIC'S SYNDROME TREAT

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Devic's Syndrome Treatment market report include:
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Viela Bio, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 230.71 Million
Forecasted Market Value ( USD ) by 2030 $ 290.17 Million
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Neuromyelitis Optica - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Guillain-Barre Syndrome Market - Global Forecast 2025-2030 - Product Image

Guillain-Barre Syndrome Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Guillain-Barre Syndrome Drugs: Market Share, and Growth Analysis by Product Type (Immunoglobulin Therapy, Plasma Exchange, Corticosteroids), Application, End User, Technology - Product Image

Guillain-Barre Syndrome Drugs: Market Share, and Growth Analysis by Product Type (Immunoglobulin Therapy, Plasma Exchange, Corticosteroids), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Guillain-Barre Syndrome Drugs Market Report 2025 - Product Image

Guillain-Barre Syndrome Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Market

Neuromyelitis Optica (NMO) is a rare autoimmune disorder of the central nervous system (CNS) that affects the optic nerves and spinal cord. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to permanent vision loss and paralysis. Treatment of NMO is focused on reducing inflammation and preventing further damage to the CNS. Drugs used to treat NMO include corticosteroids, immunosuppressants, and monoclonal antibodies. Corticosteroids are used to reduce inflammation and prevent further damage to the CNS. Immunosuppressants are used to reduce the activity of the immune system and prevent further attacks. Monoclonal antibodies are used to target specific molecules involved in the autoimmune response. The NMO drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of NMO and the development of new treatments. Companies in the NMO drug market include Biogen, Alexion Pharmaceuticals, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.